Mitral valve interventions in heart failure. (19th April 2018)

• Record Type: Journal Article
• Authors: Lavall, Daniel; Hagendorff, Andreas; Schirmer, Stephan H.; Böhm, Michael; Borger, Michael A.; Laufs, Ulrich
• Is Part Of: ESC heart failure. Volume 5:Number 4(2018)
• Page Start: 552
• Page End: 561
• Publication Date: 2018-04-19
• Subjects: Heart failure -- Secondary mitral regurgitation -- Hemodynamic -- Transcatheter mitral valve repair -- Surgical mitral vale repair; Heart failure -- Periodicals; 616.129005
• DOI: 10.1002/ehf2.12287
• Languages: English
• ISSNs: 2055-5822

Abstract

Abstract: Secondary mitral regurgitation (MR) results from left ventricular dilatation and dysfunction. Quantification of secondary MR is challenging because of the underlying myocardial disease. Clinical and echocardiographic evaluation requires a multi‐parametric approach. Severe secondary MR occurs in up to one‐fourth of patients with heart failure with reduced ejection fraction, which is associated with a mortality rate of 40% to 50% in 3 years. Percutaneous edge‐to‐edge mitral valve repair (MitraClip) has emerged as an alternative to surgical valve repair to improve symptoms, functional capacity, heart failure hospitalizations, and cardiac haemodynamics. Further new transcatheter strategies addressing MR are evolving. The Carillion, Cardioband, and Mitralign devices were designed to reduce the annulus dilatation, which is a frequent and important determinant of secondary MR. Several transcatheter mitral valve replacement systems (Tendyne, CardiAQ‐Edwards, Neovasc, Tiara, Intrepid, Caisson, HighLife, MValve System, and NCSI NaviGate Mitral) are emerging because valve replacement might be more durable compared with valve repair. In small studies, these interventional therapies demonstrated feasibility and efficiency to reduce MR and to improve heart failure symptoms. However, neither transcatheter nor surgical mitral valve repair or replacement has been proven to impact on the prognosis of heart failure patients with severe MR, which remains high with a mortality rate of 14–20% at 1 year. To date, the primary indication for treatment of secondary severe MR is the amelioration of symptoms, reinforcing the value of a Heart Team discussion. Randomized studies to investigate the treatment effect and long‐term outcome for any transcatheter or surgical mitral valve intervention compared with optimized medical treatment are urgently needed and underway.